

STABILIS PHARMA INC.
BALANCE SHEET AS AT MARCH 31, 2018

		Amount in USD	
		31-Mar-18	31-Mar-17
A ASSETS			
I Current assets			
(a) Financial assets			
(i) Cash and cash equivalents	1	2,119	8,426
(ii) Other financial assets	2	2,876	-
Total current assets		4,995	8,426
TOTAL ASSETS		4,995	8,426
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital			
	3	1,000	1,000
(b) Other equity			
	4	520	3,926
Total Equity		1,520	4,926
II Liabilities			
1 Current liabilities			
(a) Financial liabilities			
(i) Trade payables	5	3,475	2,500
(b) Current income tax liabilities			
	6	-	1,000
Total current liabilities		3,475	3,500
TOTAL EQUITY AND LIABILITIES		4,995	8,426

STABILIS PHARMA INC.
STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2018

Amount in USD

Particulars	Note No.	31-Mar-18	31-Mar-17
1 Revenue from operations	7	-	30,883
2 Other Income	8	-	145,902
3 Total Revenue (1+2)		<u>-</u>	<u>176,785</u>
4 Expenses			
(a) Cost of material consumed		-	24,798
(d) Finance costs	9	366	415
(d) Other expenses	10	3,040	4,247
Total expenses		<u>3,406</u>	<u>29,460</u>
5 Profit / (Loss) before exceptional items and taxes (3-4)		<u>(3,406)</u>	<u>147,325</u>
6 Exceptional Item		-	-
7 Profit / (Loss) before taxes (5+6)		<u>(3,406)</u>	<u>147,325</u>
8 Tax Expense:			
(1) Current tax		-	1,000
(2) Deferred tax		-	-
Total tax expenses		<u>-</u>	<u>1,000</u>
VII Profit / (Loss) for the year after tax		<u>(3,406)</u>	<u>146,325</u>

STABILIS PHARMA INC.
STATEMENT OF CHANGES IN EQUITY
FOR THE YEARS ENDED MARCH 31, 2018 AND MARCH 31, 2017

(A) Equity share capital

Particulars	Amount in USD
Balance as at March 31, 2017	1,000
Changes in equity share capital during the year	-
Balance as at March 31,2018	1,000

(B) Other equity

Amount in USD

Particulars	Reserves and Surplus		Items of other comprehensive income	Total
	Capital reserve	Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
Balance as at March 31, 2017	-	3,926	-	3,926
Profit/loss for the year	-	(3,406)	-	(3,406)
Other comprehensive income for the year (net of tax)	-	-	-	-
Total comprehensive income	-	(3,406)	-	(3,406)
Balance as at March 31,2018	-	520	-	520

STABILIS PHARMA INC.
Notes forming part of financial statement

Note

No.		Amount in USD	
1	Cash and cash equivalents		
	Particulars	31-Mar-18	31-Mar-17
	Balances with banks:		
	In current accounts	2,119	8,426
	Total	2,119	8,426
2	Other financial assets		
	Particulars	31-Mar-18	31-Mar-17
	Advances to related parties	2,876	
	Total	2,876	-
3	Share capital		
	Particulars	31-Mar-18	31-Mar-17
	Issued, subscribed and fully paid-up		
	Equity share capital	1,000	1,000
	Total	1,000	1,000
4	Reserves and surplus		
	Particulars	31-Mar-18	31-Mar-17
	Surplus in statement of profit and loss		
	Opening balance	3,926	(142,399)
	Add: Profit / (Loss) for the year	(3,406)	146,325
	Closing balance	520	3,926
	Total	520	3,926
5	Trade payables		
	Particulars	31-Mar-18	31-Mar-17
	Trade Payable	3,475	2,500
	Total	3,475	2,500
6	Current Income tax liability		
	Particulars	31-Mar-18	31-Mar-17
	Provision for income tax (net of advance tax)	-	1,000
	Total	-	1,000

STABILIS PHARMA INC.
Notes forming part of financial statement

Note

No.

		Amount in USD	
7	Revenue from operations		
	Particulars	31-Mar-18	31-Mar-17
	Sale of product	-	30,883
	Total	-	30,883
8	Other Income		
	Particulars	31-Mar-18	31-Mar-17
	Other Income	-	145,902
	Total	-	145,902
9	Finance cost		
	Particulars	31-Mar-18	31-Mar-17
	Bank charges	366	415
	Total	366	415
10	Other expenses		
	Particulars	31-Mar-18	31-Mar-17
	Net loss on foreign currency transactions	-	-
	Rates & Taxes	1,290	1,560
	Payment to auditors - For statutory audit	1,750	1,942
	Miscellaneous expense	-	745
	Total	3,040	4,247